CDx Approvals and Clinical Evidence: What FDA Moves Tell Us

The FDA's approval of Natera's Signatera CDx as a companion diagnostic for muscle-invasive bladder cancer (MIBC) represents more than another regulatory tick box. It's the first time the agency has cleared personalised molecular residual disease (MRD) testing to actively guide treatment decisions—not just monitor outcomes. For regulatory affairs teams working on precision diagnostics, software-driven devices, or any technology where clinical utility hinges on actionable biomarkers, this approval offers a masterclass in evidence strategy. Meanwhile, Boston Scientific's positive pivotal trial data for its coronary intravascular lithotripsy (IVL) catheter signals another evidence milestone, reminding us that robust clinical validation remains the currency of regulatory success across both diagnostics and therapeutic devices.

Why the Signatera CDx Approval Matters Beyond Bladder Cancer

Companion diagnostics have traditionally existed to identify patients likely to respond to a specific drug—think HER2 testing for trastuzumab or PD-L1 for checkpoint inhibitors. Signatera CDx shifts this paradigm. It's a circulating tumour DNA (ctDNA) test that creates a patient-specific genomic signature, then tracks molecular residual disease post-surgery. The crucial difference: the FDA has now endorsed its use to inform treatment escalation decisions. If MRD is detected, clinicians can confidently offer adjuvant immunotherapy. If it's negative, patients may avoid unnecessary systemic treatment.

This 'Treatment on MRD' (TOMR) approach required Natera to demonstrate not just analytical validity—that the test accurately detects ctDNA—but clinical utility: that acting on the test result improves patient management. That's a higher bar, particularly for a personalised test where each assay is designed bespoke for an individual patient's tumour mutations. The regulatory pathway involved extensive bridging studies, alignment with FDA on endpoints, and crucially, integration with prospective clinical trial data where the diagnostic informed therapeutic decisions.

For device manufacturers, especially those in the in vitro diagnostic (IVD) space under FDA's 510(k) or PMA frameworks—or IVDR in Europe—this approval underscores three critical realities. First, personalised or adaptive algorithms require meticulous validation frameworks that satisfy regulatory scrutiny on reproducibility and clinical meaningfulness. Second, demonstrating clinical utility increasingly means embedding your device within prospective interventional studies, not relying solely on retrospective data. Third, the regulatory conversation around AI-driven or software-based diagnostics is maturing: regulators want to see real-world impact on clinical decision-making, not just correlation with outcomes.

Boston Scientific's Coronary IVL Data: Evidence Strategy in Therapeutic Devices

Across the Atlantic (and regulatory divide), Boston Scientific's announcement of positive pivotal trial data for its coronary intravascular lithotripsy catheter offers a parallel lesson in evidence generation. IVL—using sonic pressure waves to fracture severely calcified coronary plaques—has already proven successful in peripheral arteries. Expanding into coronary indications required a dedicated pivotal study demonstrating safety and effectiveness in a distinct patient population with higher clinical risk.

Boston Scientific didn't repurpose peripheral data and hope for the best. They ran a prospective, adequately powered trial with endpoints aligned to FDA expectations for high-risk cardiovascular devices. The company has indicated it will now proceed with a regulatory submission, likely under the PMA pathway given the novel mechanism and indication. This disciplined approach—investing in fit-for-purpose clinical data even when adjacent approvals exist—reflects mature regulatory strategy. It also highlights the growing sophistication of FDA and notified body expectations: predicate claims or literature-based equivalence rarely suffice when you're extending technology into new anatomical territories or higher-risk populations.

For RA teams, the takeaway is clear: regulatory success is not about gaming pathways or exploiting loopholes. It's about aligning clinical evidence with the real-world clinical question regulators and clinicians need answered. Both the Signatera CDx and Boston Scientific cases exemplify this alignment—each knew the endpoint that mattered, designed studies to address it directly, and engaged early with regulators to ensure mutual understanding.

What This Means for Your Team

If you're developing companion diagnostics, liquid biopsy platforms, or any IVD that informs treatment selection, the Signatera CDx approval should prompt immediate reflection on your clinical evidence plan. Are you only demonstrating analytical and clinical validity, or are you building the utility case that shows acting on your test improves outcomes or clinical management? Regulators—FDA, notified bodies under IVDR, and increasingly MHRA—are tightening expectations around clinical utility, especially for high-stakes tests. If your device sits at the intersection of diagnostics and therapeutics, consider early engagement (FDA's Pre-Submission programme, notified body pre-assessment, or MHRA's Innovation Office) to align on acceptable endpoints and study designs.

For therapeutic device manufacturers, Boston Scientific's disciplined approach to expanding IVL into coronary indications is the model. If you're planning label expansions, new indications, or first-in-class claims, resist the temptation to lean heavily on existing approvals or literature equivalence. Regulators have limited appetite for extrapolation when the clinical risk profile or patient population changes meaningfully. Budget for pivotal data. Design studies that directly address the clinical question your new indication poses. And engage early to validate your regulatory pathway—whether that's FDA PMA, De Novo, EU MDR conformity assessment, or UK UKCA post-transition.

Both stories also reinforce a broader truth: regulatory strategy and clinical development are inseparable. Your regulatory pathway should emerge from your clinical evidence plan, not the other way around. This requires cross-functional alignment from the earliest stages—regulatory, clinical, quality, and commercial teams working from shared assumptions about what constitutes 'sufficient' evidence. It also means investing in regulatory intelligence: understanding not just what's written in guidance documents, but how regulators are actually reviewing similar devices, what questions they're asking, and where the precedent is moving.

Navigating the Global Regulatory Landscape

While these approvals centre on FDA, the implications ripple across jurisdictions. Under IVDR, companion diagnostics intended to inform therapy decisions face stringent conformity assessment requirements, typically requiring notified body involvement and robust clinical evidence per Annex XIII. The clinical utility bar mirrors FDA's increasingly—notified bodies want to see that your diagnostic's result materially affects clinical management, not just that it correlates with a biomarker.

MHRA, post-Brexit, has signalled its intent to maintain high standards while offering pragmatic pathways for innovation (as evidenced by their recent commitment to supporting life sciences in Wales, reflecting a broader push for regional innovation infrastructure). For companion diagnostics, MHRA's trajectory suggests continued alignment with international best practice—expect clinical utility to remain a focus, though the UK pathway may offer faster timelines for devices with strong FDA or EU precedent.

If you're pursuing multi-market strategies, the key is harmonisation of clinical evidence. Design studies that satisfy the highest common denominator—typically FDA PMA or IVDR requirements—so you can leverage the same core data across submissions. This requires early mapping of regulatory requirements across target markets, identification of region-specific gaps (e.g., additional endpoints, population representation, or post-market commitments), and proactive engagement with each authority to validate assumptions.

Key Takeaways

• Natera's Signatera CDx approval sets a new benchmark for personalised diagnostics: demonstrating clinical utility—that acting on test results improves patient management—is now table stakes for companion diagnostics and liquid biopsy platforms.
• Boston Scientific's coronary IVL pivotal trial underscores that label expansions or new indications require dedicated clinical evidence; regulators are sceptical of extrapolation when patient populations or risk profiles change meaningfully.
• Regulatory strategy must emerge from clinical evidence planning, not the reverse. Cross-functional alignment on endpoints and study design from Day One is critical to avoiding costly pivots later.
• Global regulatory harmonisation is achievable if you design studies to meet the highest bar (typically FDA PMA or IVDR) and map region-specific requirements early. Early engagement with regulators across target markets de-risks timelines and avoids surprises.
• For devices at the diagnostic-therapeutic interface, invest in regulatory intelligence: understand how similar devices have been reviewed, what questions regulators are asking, and where precedent is evolving. Generic guidance documents rarely tell the full story.

The convergence of these approvals—personalised diagnostics guiding treatment, therapeutic devices expanding into higher-risk indications—illustrates the increasingly sophisticated regulatory landscape. Success requires more than compliance; it demands strategic foresight, robust clinical evidence, and early regulatory dialogue. Whether you're navigating FDA PMA, IVDR conformity assessment, or MHRA pathways, the lesson is consistent: invest in the evidence that answers the clinical question regulators and clinicians actually care about. That's where SMEDTEC's expertise becomes invaluable—translating regulatory expectations into actionable strategies, de-risking pathways, and ensuring your clinical development programme and regulatory submissions are aligned from the start. The regulatory bar is rising, but so too are the opportunities for well-prepared teams.